Nat Commun, 2025, 16(1):471

Endothelial-secreted Endocan activates PDGFRA and regulates vascularity and spatial phenotype in glioblastoma

Extensive neovascularization is a hallmark of glioblastoma (GBM). In addition to supplying oxygen and nutrients, vascular endothelial cells provide trophic support to GBM cells via paracrine signaling. Here we report that Endocan (ESM1), an endothelial-secreted proteoglycan, confers enhanced proliferative, migratory, and angiogenic properties to GBM cells and regulates their spatial identity. Mechanistically, Endocan exerts at least part of its functions via direct binding and activation of the PDGFRA receptor. Subsequent downstream signaling enhances chromatin accessibility of the Myc promoter and upregulates Myc expression inducing stable phenotypic changes in GBM cells. Furthermore, Endocan confers radioprotection on GBM cells in vitro and in vivo. Inhibition of Endocan-PDGFRA signaling with ponatinib increases survival in the Esm1 wild-type but not in the Esm1 knock-out mouse GBM model. Our findings identify Endocan and its downstream signaling axis as a potential target to subdue GBM recurrence and highlight the importance of vascular-tumor interactions for GBM development.

Bastola S, Pavlyukov MS, Sharma N, Ghochani Y, Nakano MA, Muthukrishnan SD, Yu SY, Kim MS, Sohrabi A, Biscola NP, Yamashita D, Anufrieva KS, Kovalenko TF, Jung G, Ganz T, OBrien B, Kawaguchi R, Qin Y, Seidlits SK, Burlingame AL, Oses-Prieto JA, Havton LA, Goldman SA, Hjelmeland AB, Nakano I, Kornblum HI

IBCH: 11792
Ссылка на статью в журнале: https://www.nature.com/articles/s41467-024-55487-1
Кол-во цитирований на 09.2025: 2
Данные статьи проверены модераторами 2025-02-01

Список научных проектов, где отмечена публикация

  1. R01NS083767. . Сommercial.
  2. R01NS087913. . Сommercial.
  3. R01CA183991. . Сommercial.
  4. R01CA201402. . Сommercial.
  5. R01NS104339. . Сommercial.
  6. RO1CA241927. . Сommercial.
  7. NS052563. . Сommercial.
  8. P50CA211015. . Сommercial.
  9. 075-15-2019-1669. . Сommercial.
  10. Identification of genes as potential targets for therapy of neurogenic tumors (January 6, 2024 — December 31, 2026). Antipova N.V.. Grant, RSF.